IAPAM Best Practices for the Injection of Botox (Botulinum Toxin Type A)

.

Introduction - Botox (Botulinum Toxin Type A)

Since first introduced to the medical community in 1989, as a treatment for eye muscle disorders, administering of Botulinum Toxin Type A: Botox® and similar neurotoxin injectables, has now become the most popular non-invasive aesthetic medical procedure performed worldwide.

Unfortunately, such pervasive market growth has lead to the undesired reality that physicians and non-medical professionals mistakenly think that all they need to do to capture a percentage of this market for their practice, is to simply hang out a sign and ’start injecting.’ Read more

Botox vs Dysport - IAPAM Expert Discussion

Given the FDA approval of the new botulinum toxin A product, Dysport, in 2009, a competitor to the well establish Botox Cosmetic, the IAPAM recently queried its members and physicians with comprehensive experience in the use of botulinum toxin injectables, to develop a report comparing these two products.  This discussion is considered a critical element in the IAPAM’s comprehensive botox training programs.

Dysport has been studied in Europe since 1988, has been available for use outside the US since 1991, and was recently approved for cosmetic use in the US in May 2009. Equally, Botox has been manufactured and studied in the US since 1985, and was officially approved by the FDA for cosmetic use in April 2002.

Botox ® and Dysport ® are not interchangeable because the products are dosed and injected differently.  To assist physicians in selecting the best product for each patient’s need, a number of physicians have offered their expert comparison of Botox ®Cosmetic and Dysport ®. Read more